Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson's disease

Neurochemistry International

Volumn 62, Issue 5, 2013, Pages 803-819

  Taylor, Juliet M ^a   Main, Bevan S ^a   Crack, Peter J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Innate immunity; Microglia; Neuroinflammation; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; OXIDOPAMINE; PARAQUAT; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROTENONE;

ADAPTIVE IMMUNITY; APOPTOSIS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENETIC MODEL; HUMAN; INNATE IMMUNITY; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION;

CENTRAL NERVOUS SYSTEM; HUMANS; INFLAMMATION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84875703698     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.12.016     Document Type: Review

References (255)

1. R.S. Akundi, Z. Huang, J. Eason, J.D. Pandya, L. Zhi, W.A. Cass, P.G. Sullivan, and H. Bueler Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice PLoS One 6 1 2011 e16038
2. F. Aloisi The role of microglia and astrocytes in CNS immune surveillance and immunopathology Adv. Exp. Med. Biol. 468 1999 123 133
3. E. Andres-Mateos, C. Perier, L. Zhang, B. Blanchard-Fillion, T.M. Greco, B. Thomas, H.S. Ko, M. Sasaki, H. Ischiropoulos, S. Przedborski, T.M. Dawson, and V.L. Dawson DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase Proc. Natl. Acad. Sci. USA 104 37 2007 14807 14812
4. E. Andres-Mateos, R. Mejias, M. Sasaki, X. Li, B.M. Lin, S. Biskup, L. Zhang, R. Banerjee, B. Thomas, L. Yang, G. Liu, M.F. Beal, D.L. Huso, T.M. Dawson, and V.L. Dawson Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) J. Neurosci. 29 50 2009 15846 15850
5. D.C. Angeles, B.H. Gan, L. Onstead, Y. Zhao, K.L. Lim, J. Dachsel, H. Melrose, M. Farrer, Z.K. Wszolek, D.W. Dickson, and E.K. Tan Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death Hum. Mutat. 32 12 2011 1390 1397
6. P.M. Antony, N.J. Diederich, and R. Balling Parkinson's disease mouse models in translational research Mamm. Genome 22 7-8 2011 401 419
7. H. Arai, T. Furuya, T. Yasuda, M. Miura, Y. Mizuno, and H. Mochizuki Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice J. Biol. Chem. 279 49 2004 51647 51653
8. D.S. Arroyo, J.A. Soria, E.A. Gaviglio, M.C. Rodriguez-Galan, and P. Iribarren Toll-like receptors are key players in neurodegeneration Int. Immunopharmacol. 11 10 2011 1415 1421
9. M. Baldereschi, M. Inzitari, P. Vanni, A. Di Carlo, and D. Inzitari Pesticide exposure might be a strong risk factor for Parkinson's disease Ann. Neurol. 63 1 2008 128
10. R.B. Banati, S.E. Daniel, and S.B. Blunt Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Mov. Disord. 13 2 1998 221 227
11. R. Bandopadhyay, A.E. Kingsbury, M.R. Cookson, A.R. Reid, I.M. Evans, A.D. Hope, A.M. Pittman, T. Lashley, R. Canet-Aviles, D.W. Miller, C. McLendon, C. Strand, A.J. Leonard, P.M. Abou-Sleiman, D.G. Healy, H. Ariga, N.W. Wood, R. de Silva, T. Revesz, J.A. Hardy, and A.J. Lees The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease Brain 127 Pt 2 2004 420 430
12. C. Barcia, C.M. Ros, V. Annese, A. Gomez, F. Ros-Bernal, D. Aguado-Yera, M.E. Martinez-Pagan, V. de Pablos, E. Fernandez-Villalba, and M.T. Herrero IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease Cell Death Dis. 2 2011 e142
13. K.J. Barnham, C.L. Masters, and A.I. Bush Neurodegenerative diseases and oxidative stress Nat. Rev. Drug Discovery 3 3 2004 205 214
14. C.J. Barnum, and M.G. Tansey Modeling neuroinflammatory pathogenesis of Parkinson's disease Prog. Brain Res. 184 2010 113 132
15. A. Beilina, M. Van Der Brug, R. Ahmad, S. Kesavapany, D.W. Miller, G.A. Petsko, and M.R. Cookson Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability Proc. Natl. Acad. Sci. USA 102 16 2005 5703 5708
16. E.J. Benner, R. Banerjee, A.D. Reynolds, S. Sherman, V.M. Pisarev, V. Tsiperson, C. Nemachek, P. Ciborowski, S. Przedborski, R.L. Mosley, and H.E. Gendelman Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons PLoS One 3 1 2008 e1376
17. D.A. Bennett, L.A. Beckett, A.M. Murray, K.M. Shannon, C.G. Goetz, D.M. Pilgrim, and D.A. Evans Prevalence of parkinsonian signs and associated mortality in a community population of older people N. Engl. J. Med. 334 2 1996 71 86
18. D. Beraud, and K.A. Maguire-Zeiss Misfolded alpha-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease Parkinsonism Relat. Disord. 18 Suppl. 1 2012 S17 S20
19. R. Beschorner, T.D. Nguyen, F. Gozalan, I. Pedal, R. Mattern, H.J. Schluesener, R. Meyermann, and J.M. Schwab CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury Acta Neuropathol. 103 6 2002 541 549
20. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 12 2000 1301 1306
21. M. Bian, J. Liu, X. Hong, M. Yu, Y. Huang, Z. Sheng, J. Fei, and F. Huang Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice PLoS One 7 6 2012 e39953
22. F. Billia, L. Hauck, F. Konecny, V. Rao, J. Shen, and T.W. Mak PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function Proc. Natl. Acad. Sci. USA 108 23 2011 9572 9577
23. W. Birkmayer, and O. Hornykiewicz The l-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson akinesis Arch. Psychiatr. Nervenkr. Z. Gesamte. Neurol. Psychiatr. 203 1962 560 574
24. S. Biskup, D.J. Moore, F. Celsi, S. Higashi, A.B. West, S.A. Andrabi, K. Kurkinen, S.W. Yu, J.M. Savitt, H.J. Waldvogel, R.L. Faull, P.C. Emson, R. Torp, O.P. Ottersen, T.M. Dawson, and V.L. Dawson Localization of LRRK2 to membranous and vesicular structures in mammalian brain Ann. Neurol. 60 5 2006 557 569
25. M.L. Block, and J.S. Hong Chronic microglial activation and progressive dopaminergic neurotoxicity Biochem. Soc. Trans. 35 Pt 5 2007 1127 1132
26. D. Blum-Degen, T. Muller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neurosci. Lett. 202 1-2 1995 17 20
27. G. Boka, P. Anglade, D. Wallach, F. Javoy-Agid, Y. Agid, and E.C. Hirsch Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease Neurosci. Lett. 172 1-2 1994 151 154
28. V. Bonifati Autosomal recessive parkinsonism Parkinsonism Relat. Disord. 18 Suppl. 1 2012 S4 S6
29. V. Brochard, B. Combadiere, A. Prigent, Y. Laouar, A. Perrin, V. Beray-Berthat, O. Bonduelle, D. Alvarez-Fischer, J. Callebert, J.M. Launay, C. Duyckaerts, R.A. Flavell, E.C. Hirsch, and S. Hunot Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease J. Clin. Invest. 119 1 2009 182 192
30. A. Carlsson, M. Lindqvist, and T. Magnusson 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists Nature 180 4596 1957 1200
31. A.R. Carta, A. Kachroo, N. Schintu, K. Xu, M.A. Schwarzschild, J. Wardas, and M. Morelli Inactivation of neuronal forebrain a receptors protects dopaminergic neurons in a mouse model of Parkinson's disease J. Neurochem. 111 6 2009 1478 1489
32. A.R. Carta, L. Frau, A. Pisanu, J. Wardas, S. Spiga, and E. Carboni Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model Neuroscience 194 2011 250 261
33. M. Carty, and A.G. Bowie Evaluating the role of Toll-like receptors in diseases of the central nervous system Biochem. Pharmacol. 81 7 2011 825 837
34. M.J. Casarejos, J. Menendez, R.M. Solano, J.A. Rodriguez-Navarro, J. Garcia de Yebenes, and M.A. Mena Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline J. Neurochem. 97 4 2006 934 946
35. K.R. Chaudhuri, and A.H. Schapira Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol. 8 5 2009 464 474
36. V.S. Chauhan, D.G. Sterka Jr., S.R. Furr, A.B. Young, and I. Marriott NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens Glia 57 4 2009 414 423
37. H. Chen, S.M. Zhang, M.A. Hernan, M.A. Schwarzschild, W.C. Willett, G.A. Colditz, F.E. Speizer, and A. Ascherio Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch. Neurol. 60 8 2003 1059 1064
38. H. Chen, E. Jacobs, M.A. Schwarzschild, M.L. McCullough, E.E. Calle, M.J. Thun, and A. Ascherio Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Ann. Neurol. 58 6 2005 963 967
39. L. Chen, B. Cagniard, T. Mathews, S. Jones, H.C. Koh, Y. Ding, P.M. Carvey, Z. Ling, U.J. Kang, and X. Zhuang Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice J. Biol. Chem. 280 22 2005 21418 21426
40. H. Chen, E.J. O'Reilly, M.A. Schwarzschild, and A. Ascherio Peripheral inflammatory biomarkers and risk of Parkinson's disease Am. J. Epidemiol. 167 1 2008 90 95
41. M.F. Chesselet In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp. Neurol. 209 1 2008 22 27
42. S.J. Chinta, and J.K. Andersen Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease Free Radic. Res. 45 1 2011 53 58
43. K.K. Chung, B. Thomas, X. Li, O. Pletnikova, J.C. Troncoso, L. Marsh, V.L. Dawson, and T.M. Dawson S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function Science 304 5675 2004 1328 1331
44. F. Cicchetti, A.L. Brownell, K. Williams, Y.I. Chen, E. Livni, and O. Isacson Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging Eur. J. Neurosci. 15 6 2002 991 998
45. F. Cicchetti, N. Lapointe, A. Roberge-Tremblay, M. Saint-Pierre, L. Jimenez, B.W. Ficke, and R.E. Gross Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats Neurobiol. Dis. 20 2 2005 360 371
46. F. Cicchetti, J. Drouin-Ouellet, and R.E. Gross Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol. Sci. 30 9 2009 475 483
47. A. Ciesielska, I. Joniec, A. Przybylkowski, G. Gromadzka, I. Kurkowska-Jastrzebska, A. Czlonkowska, and A. Czlonkowski Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease Acta Neurobiol. Exp. 63 2 2003 117 126
48. L.N. Clark, S. Afridi, H. Mejia-Santana, J. Harris, E.D. Louis, L.J. Cote, H. Andrews, A. Singleton, F. Wavrant De-Vrieze, J. Hardy, R. Mayeux, S. Fahn, C. Waters, B. Ford, S. Frucht, R. Ottman, and K. Marder Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations Mov. Disord. 19 7 2004 796 800
49. I.E. Clark, M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, J.H. Seol, S.J. Yoo, B.A. Hay, and M. Guo Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin Nature 441 7097 2006 1162 1166
50. E. Colla, P. Coune, Y. Liu, O. Pletnikova, J.C. Troncoso, T. Iwatsubo, B.L. Schneider, and M.K. Lee Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo J. Neurosci. 32 10 2012 3306 3320
51. M.I. Combrinck, V.H. Perry, and C. Cunningham Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease Neuroscience 112 1 2002 7 11
52. K.A. Conway, S.J. Lee, J.C. Rochet, T.T. Ding, J.D. Harper, R.E. Williamson, and P.T. Lansbury Jr. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants Ann. N. Y. Acad. Sci. 920 2000 42 45
53. K.A. Conway, S.J. Lee, J.C. Rochet, T.T. Ding, R.E. Williamson, and P.T. Lansbury Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc. Natl. Acad. Sci. USA 97 2 2000 571 576
54. M.R. Cookson, and O. Bandmann Parkinson's disease: insights from pathways Hum. Mol. Genet. 19 R1 2010 R21 R27
55. E.M. Cornejo Castro, J. Waak, S.S. Weber, F.C. Fiesel, P. Oberhettinger, M. Schutz, I.B. Autenrieth, W. Springer, and P.J. Kahle Parkinson's disease-associated DJ-1 modulates innate immunity signaling in Caenorhabditis elegans J. Neural. Transm. 117 5 2010 599 604
56. L. Correia Guedes, J.J. Ferreira, M.M. Rosa, M. Coelho, V. Bonifati, and C. Sampaio Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review Parkinsonism Relat. Disord. 16 4 2010 237 242
57. J.T. Coyle, and P. Puttfarcken Oxidative stress, glutamate, and neurodegenerative disorders Science 262 5134 1993 689 695
58. C. Cunningham, D.C. Wilcockson, D. Boche, and V.H. Perry Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease J. Virol. 79 8 2005 5174 5184
59. A. Czlonkowska, M. Kohutnicka, I. Kurkowska-Jastrzebska, and A. Czlonkowski Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model Neurodegeneration 5 2 1996 137 143
60. J.P. Daher, M. Ying, R. Banerjee, R.S. McDonald, M.D. Hahn, L. Yang, M. Flint Beal, B. Thomas, V.L. Dawson, T.M. Dawson, and D.J. Moore Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons Mol. Neurodegener. 4 2009 34
61. P. Danoy, K. Pryce, J. Hadler, L.A. Bradbury, C. Farrar, J. Pointon, M. Australo-Anglo-American Spondyloarthritis Consortium Ward, M. Weisman, J.D. Reveille, B.P. Wordsworth, M.A. Stone, Spondyloarthritis Research Consortium of Canada, W.P. Maksymowych, P. Rahman, D. Gladman, R.D. Inman, and M.A. Brown Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease PLoS Genet. 6 12 2010 e1001195
62. W. Dauer, N. Kholodilov, M. Vila, A.C. Trillat, R. Goodchild, K.E. Larsen, R. Staal, K. Tieu, Y. Schmitz, C.A. Yuan, M. Rocha, V. Jackson-Lewis, S. Hersch, D. Sulzer, S. Przedborski, R. Burke, and R. Hen Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP Proc. Natl. Acad. Sci. USA 99 22 2002 14524 14529
63. T.M. Dawson, and V.L. Dawson The role of parkin in familial and sporadic Parkinson's disease Mov. Disord. 25 Suppl. 1 2010 S32 S39
64. T.M. Dawson, H.S. Ko, and V.L. Dawson Genetic animal models of Parkinson's disease Neuron 66 5 2010 646 661
65. L.M. de Lau, and M.M. Breteler Epidemiology of Parkinson's disease Lancet Neurol. 5 6 2006 525 535
66. M. Diedrich, T. Kitada, G. Nebrich, A. Koppelstaetter, J. Shen, C. Zabel, J. Klose, and L. Mao Brain region specific mitophagy capacity could contribute to selective neuronal vulnerability in Parkinson's disease Proteome Sci. 9 2011 59
67. R.J. Dobbs, A. Charlett, A.G. Purkiss, S.M. Dobbs, C. Weller, and D.W. Peterson Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism Acta Neurol. Scand. 100 1 1999 34 41
68. Z. Dong, B. Ferger, J. Feldon, and H. Bueler Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP J. Neurobiol. 53 1 2002 1 10
69. R.E. Drolet, J.M. Sanders, and J.T. Kern Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions J. Neurogenet. 25 4 2011 140 151
70. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, and S.M. Paul Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. USA 98 25 2001 14669 14674
71. D.C. Duke, L.B. Moran, R.K. Pearce, and M.B. Graeber The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability Neurogenetics 8 2 2007 83 94
72. N. Dzamko, F. Inesta-Vaquera, J. Zhang, C. Xie, H. Cai, S. Arthur, L. Tan, H. Choi, N. Gray, P. Cohen, P. Pedrioli, K. Clark, and D.R. Alessi The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling PLoS One 7 6 2012 e39132
73. K.L. Emmer, E.A. Waxman, J.P. Covy, and B.I. Giasson E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment J. Biol. Chem. 286 40 2011 35104 35118
74. S. Fahn, and G. Cohen The oxidant stress hypothesis in Parkinson's disease: evidence supporting it Ann. Neurol. 32 6 1992 804 812
75. T.N. Ferraro, G.T. Golden, M. DeMattei, T.A. Hare, and R.G. Fariello Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse Neuropharmacology 25 9 1986 1071 1074
76. R.A. Floyd Antioxidants, oxidative stress, and degenerative neurological disorders Proc. Soc. Exp. Biol. Med. 222 3 1999 236 245
77. T.C. Frank-Cannon, T. Tran, K.A. Ruhn, T.N. Martinez, J. Hong, M. Marvin, M. Hartley, I. Trevino, D.E. O'Brien, B. Casey, M.S. Goldberg, and M.G. Tansey Parkin deficiency increases vulnerability to inflammation-related nigral degeneration J. Neurosci. 28 43 2008 10825 10834
78. H.M. Gao, B. Liu, W. Zhang, and J.S. Hong Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease FASEB J. 17 13 2003 1954 1956
79. H.M. Gao, P.T. Kotzbauer, K. Uryu, S. Leight, J.Q. Trojanowski, and V.M. Lee Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration J. Neurosci. 28 30 2008 7687 7698
80. H.M. Gao, F. Zhang, H. Zhou, W. Kam, B. Wilson, and J.S. Hong Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease Environ. Health Perspect. 119 6 2011 807 814
81. A. Gardet, Y. Benita, C. Li, B.E. Sands, I. Ballester, C. Stevens, J.R. Korzenik, J.D. Rioux, M.J. Daly, R.J. Xavier, and D.K. Podolsky LRRK2 is involved in the IFN-gamma response and host response to pathogens J. Immunol. 185 9 2010 5577 5585
82. C.A. Gautier, T. Kitada, and J. Shen Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress Proc. Natl. Acad. Sci. USA 105 32 2008 11364 11369
83. S. George, S.S. Mok, M. Nurjono, S. Ayton, D.I. Finkelstein, C.L. Masters, Q.X. Li, and J.G. Culvenor Alpha-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced alpha-synuclein and PINK1 levels after rotenone treatment J. Mol. Neurosci. 42 2 2010 243 254
84. A. Gerhard, N. Pavese, G. Hotton, F. Turkheimer, M. Es, A. Hammers, K. Eggert, W. Oertel, R.B. Banati, and D.J. Brooks In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiol. Dis. 21 2 2006 404 412
85. M. Gerlach, D. Ben-Shachar, P. Riederer, and M.B. Youdim Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63 3 1994 793 807
86. B.I. Giasson, H. Ischiropoulos, V.M. Lee, and J.Q. Trojanowski The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases Free Radic. Biol. Med. 32 12 2002 1264 1275
87. F. Gillardon Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110 5 2009 1514 1522
88. F. Gillardon, R. Schmid, and H. Draheim Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity Neuroscience 208 2012 41 48
89. Y. Glinka, M. Gassen, and M.B. Youdim Mechanism of 6-hydroxydopamine neurotoxicity J. Neural. Transm. 50 1997 55 66
90. J.P. Godbout, J. Chen, J. Abraham, A.F. Richwine, B.M. Berg, K.W. Kelley, and R.W. Johnson Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system FASEB J. 19 10 2005 1329 1331
91. J.C. Greene, A.J. Whitworth, I. Kuo, L.A. Andrews, M.B. Feany, and L.J. Pallanck Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants Proc. Natl. Acad. Sci. USA 100 7 2003 4078 4083
92. E. Greggio, S. Jain, A. Kingsbury, R. Bandopadhyay, P. Lewis, A. Kaganovich, M.P. van der Brug, A. Beilina, J. Blackinton, K.J. Thomas, R. Ahmad, D.W. Miller, S. Kesavapany, A. Singleton, A. Lees, R.J. Harvey, K. Harvey, and M.R. Cookson Kinase activity is required for the toxic effects of mutant LRRK2/dardarin Neurobiol. Dis. 23 2 2006 329 341
93. S.P. Gupta, S. Patel, S. Yadav, A.K. Singh, S. Singh, and M.P. Singh Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation? Neurochem. Res. 35 8 2010 1206 1213
94. J.N. Guzman, J. Sanchez-Padilla, D. Wokosin, J. Kondapalli, E. Ilijic, P.T. Schumacker, and D.J. Surmeier Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 Nature 468 7324 2010 696 700
95. G.M. Halliday, A. Ophof, M. Broe, P.H. Jensen, E. Kettle, H. Fedorow, M.I. Cartwright, F.M. Griffiths, C.E. Shepherd, and K.L. Double Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease Brain 128 Pt 11 2005 2654 2664
96. S.H. Han, Y.H. Kim, and I. Mook-Jung RAGE: the beneficial and deleterious effects by diverse mechanisms of actions Mol. Cells 31 2 2011 91 97
97. D.B. Hancock, E.R. Martin, J.M. Stajich, R. Jewett, M.A. Stacy, B.L. Scott, J.M. Vance, and W.K. Scott Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease Arch. Neurol. 64 4 2007 576 580
98. D.B. Hancock, E.R. Martin, G.M. Mayhew, J.M. Stajich, R. Jewett, M.A. Stacy, B.L. Scott, J.M. Vance, and W.K. Scott Pesticide exposure and risk of Parkinson's disease: a family-based case-control study BMC Neurol. 8 2008 6
99. M.E. Haque, K.J. Thomas, C. D'Souza, S. Callaghan, T. Kitada, R.S. Slack, P. Fraser, M.R. Cookson, A. Tandon, and D.S. Park Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP Proc. Natl. Acad. Sci. USA 105 5 2008 1716 1721
100. M.E. Haque, M.P. Mount, F. Safarpour, E. Abdel-Messih, S. Callaghan, C. Mazerolle, T. Kitada, R.S. Slack, V. Wallace, J. Shen, H. Anisman, and D.S. Park Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1 J. Biol. Chem. 287 27 2012 23162 23170
101. C.H. Hawkes Parkinson's disease and aging: same or different process? Mov. Disord. 23 1 2008 47 53
102. Y. He, S. Appel, and W. Le Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum Brain Res. 909 1-2 2001 187 193
103. D.G. Healy, M. Falchi, S.S. O'Sullivan, V. Bonifati, A. Durr, S. Bressman, A. Brice, J. Aasly, C.P. Zabetian, S. Goldwurm, J.J. Ferreira, E. Tolosa, D.M. Kay, C. Klein, D.R. Williams, C. Marras, A.E. Lang, Z.K. Wszolek, J. Berciano, A.H. Schapira, T. Lynch, K.P. Bhatia, T. Gasser, A.J. Lees, and N.W. Wood Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol. 7 7 2008 583 590
104. H.Y. Heo, J.M. Park, C.H. Kim, B.S. Han, K.S. Kim, and W. Seol LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity Exp. Cell Res. 316 4 2010 649 656
105. M.A. Hernan, G. Logroscino, and L.A. Garcia Rodriguez Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease Neurology 66 7 2006 1097 1099
106. A.J. Herrera, A. Castano, J.L. Venero, J. Cano, and A. Machado The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system Neurobiol. Dis. 7 4 2000 429 447
107. D.S. Higgins Jr., and J.T. Greenamyre [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study J. Neurosci. 16 12 1996 3807 3816
108. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 4 2009 382 397
109. E.C. Hirsch, S. Hunot, and A. Hartmann Neuroinflammatory processes in Parkinson's disease Parkinsonism & related disorders 11 Suppl. 1 2005 S9
110. E.C. Hirsch, S. Vyas, and S. Hunot Neuroinflammation in Parkinson's disease Parkinsonism Relat. Disord. 18 Suppl. 1 2012 S210 S212
111. S. Hunot, V. Bernard, B. Faucheux, F. Boissiere, E. Leguern, C. Brana, P.P. Gautris, J. Guerin, B. Bloch, Y. Agid, and E.C. Hirsch Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease J. Neural Transm. 103 8-9 1996 1043 1052
112. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, and E.C. Hirsch Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 2 1996 355 363
113. S. Hunot, B. Brugg, D. Ricard, P.P. Michel, M.P. Muriel, M. Ruberg, B.A. Faucheux, Y. Agid, and E.C. Hirsch Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease Proc. Natl. Acad. Sci. USA 94 14 1997 7531 7536
114. S. Hunot, N. Dugas, B. Faucheux, A. Hartmann, M. Tardieu, P. Debre, Y. Agid, B. Dugas, and E.C. Hirsch FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells J. Neurosci. 19 9 1999 3440 3447
115. D.H. Hyun, M. Lee, N. Hattori, S. Kubo, Y. Mizuno, B. Halliwell, and P. Jenner Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome J. Biol. Chem. 277 32 2002 28572 28577
116. D.H. Hyun, M. Lee, B. Halliwell, and P. Jenner Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults J. Neurosci. Res. 82 2 2005 232 244
117. K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol. 106 6 2003 518 526
118. M.M. Iravani, C.C. Leung, M. Sadeghian, C.O. Haddon, S. Rose, and P. Jenner The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation Eur. J. Neurosci. 22 2 2005 317 330
119. M.M. Iravani, M. Sadeghian, C.C. Leung, P. Jenner, and S. Rose Lipopolysaccharide-induced nigral inflammation leads to increased IL-1beta tissue content and expression of astrocytic glial cell line-derived neurotrophic factor Neurosci. Lett. 510 2 2012 138 142
120. I. Irrcher, H. Aleyasin, E.L. Seifert, S.J. Hewitt, S. Chhabra, M. Phillips, A.K. Lutz, M.W. Rousseaux, L. Bevilacqua, A. Jahani-Asl, S. Callaghan, J.G. MacLaurin, K.F. Winklhofer, P. Rizzu, P. Rippstein, R.H. Kim, C.X. Chen, E.A. Fon, R.S. Slack, M.E. Harper, H.M. McBride, T.W. Mak, and D.S. Park Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics Hum. Mol. Genet. 19 19 2010 3734 3746
121. J.M. Itier, P. Ibanez, M.A. Mena, N. Abbas, C. Cohen-Salmon, G.A. Bohme, M. Laville, J. Pratt, O. Corti, L. Pradier, G. Ret, C. Joubert, M. Periquet, F. Araujo, J. Negroni, M.J. Casarejos, S. Canals, R. Solano, A. Serrano, E. Gallego, M. Sanchez, P. Denefle, J. Benavides, G. Tremp, T.A. Rooney, A. Brice, and J. Garcia de Yebenes Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse Hum. Mol. Genet. 12 18 2003 2277 2291
122. J. Jankovic, and M. Stacy Medical management of levodopa-associated motor complications in patients with Parkinson's disease CNS Drugs 21 8 2007 677 692
123. J.N. Johannessen, C.C. Chiueh, R.S. Burns, and S.P. Markey Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects Life Sci. 36 3 1985 219 224
124. E. Junn, and M.M. Mouradian Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine Neurosci. Lett. 320 3 2002 146 150
125. P.J. Kahle, J. Waak, and T. Gasser DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders Free Radic. Biol. Med. 47 10 2009 1354 1361
126. Y.V. Kalkonde, W.W. Morgan, J. Sigala, S.K. Maffi, C. Condello, W. Kuziel, S.S. Ahuja, and S.K. Ahuja Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration Brain Res. 1128 1 2007 1 11
127. F. Kamel, C. Tanner, D. Umbach, J. Hoppin, M. Alavanja, A. Blair, K. Comyns, S. Goldman, M. Korell, J. Langston, G. Ross, and D. Sandler Pesticide exposure and self-reported Parkinson's disease in the agricultural health study Am. J. Epidemiol. 165 4 2007 364 374
128. A. Kastner, E.C. Hirsch, O. Lejeune, F. Javoy-Agid, O. Rascol, and Y. Agid Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59 3 1992 1080 1089
129. R.H. Kim, P.D. Smith, H. Aleyasin, S. Hayley, M.P. Mount, S. Pownall, A. Wakeham, A.J. You-Ten, S.K. Kalia, P. Horne, D. Westaway, A.M. Lozano, H. Anisman, D.S. Park, and T.W. Mak Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress Proc. Natl. Acad. Sci. USA 102 14 2005 5215 5220
130. B. Kim, M.S. Yang, D. Choi, J.H. Kim, H.S. Kim, W. Seol, S. Choi, I. Jou, E.Y. Kim, and E.H. Joe Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia PLoS One 7 4 2012 e34693
131. C. Knott, G. Stern, and G.P. Wilkin Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Mol. Cell. Neurosci. 16 6 2000 724 739
132. M. Kohutnicka, E. Lewandowska, I. Kurkowska-Jastrzebska, A. Czlonkowski, and A. Czlonkowska Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Immunopharmacology 39 3 1998 167 180
133. U. Kumari, and E.K. Tan LRRK2 in Parkinson's disease: genetic and clinical studies from patients FEBS J. 276 22 2009 6455 6463
134. G. Kunikowska, and P. Jenner 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase Brain Res. 922 1 2001 51 64
135. I. Kurkowska Jastrzebska, A. Wrońska, M. Kohutnicka, A. Członkowski, and A. Członkowska MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease Acta Neurobiol. Exp. 59 1 1999 1
136. I. Kurkowska-Jastrzebska, A. Wronska, M. Kohutnicka, A. Czlonkowski, and A. Czlonkowska The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse Exp. Neurol. 156 1 1999 50 61
137. L.J. Lawson, V.H. Perry, P. Dri, and S. Gordon Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain Neuroscience 39 1 1990 151 170
138. J.E. Le Belle, N.M. Orozco, A.A. Paucar, J.P. Saxe, J. Mottahedeh, A.D. Pyle, H. Wu, and H.I. Kornblum Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner Cell Stem Cell 8 1 2011 59 71
139. J.K. Lee, T. Tran, and M.G. Tansey Neuroinflammation in Parkinson's disease J. Neuroimmune Pharmacol. 4 4 2009 419 429
140. K.W. Lee, X. Zhao, J.Y. Im, H. Grosso, W.H. Jang, T.W. Chan, P.K. Sonsalla, D.C. German, H. Ichijo, E. Junn, and M.M. Mouradian Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation PLoS One 7 1 2012 e29935
141. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 9680 2009 2055 2066
142. Y. Li, W. Liu, T.F. Oo, L. Wang, Y. Tang, V. Jackson-Lewis, C. Zhou, K. Geghman, M. Bogdanov, S. Przedborski, M.F. Beal, R.E. Burke, and C. Li Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease Nat. Neurosci. 12 7 2009 826 828
143. X. Li, D.J. Moore, Y. Xiong, T.M. Dawson, and V.L. Dawson Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2 J. Biol. Chem. 285 38 2010 29569 29576
144. X. Li, J.C. Patel, J. Wang, M.V. Avshalumov, C. Nicholson, J.D. Buxbaum, G.A. Elder, M.E. Rice, and Z. Yue Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S J. Neurosci. 30 5 2010 1788 1797
145. G.T. Liberatore, V. Jackson-Lewis, S. Vukosavic, A.S. Mandir, M. Vila, W.G. McAuliffe, V.L. Dawson, T.M. Dawson, and S. Przedborski Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nat. Med. 5 12 1999 1403 1409
146. X. Lin, L. Parisiadou, X.L. Gu, L. Wang, H. Shim, L. Sun, C. Xie, C.X. Long, W.J. Yang, J. Ding, Z.Z. Chen, P.E. Gallant, J.H. Tao-Cheng, G. Rudow, J.C. Troncoso, Z. Liu, Z. Li, and H. Cai Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein Neuron 64 6 2009 807 827
147. H.H. Liou, R.C. Chen, Y.F. Tsai, W.P. Chen, Y.C. Chang, and M.C. Tsai Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies Toxicol. Appl. Pharmacol. 137 1 1996 34 41
148. A.K. Liou, R.K. Leak, L. Li, and M.J. Zigmond Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway Neurobiol. Dis. 32 1 2008 116 124
149. J. Lipski, R. Nistico, N. Berretta, E. Guatteo, G. Bernardi, and N.B. Mercuri L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease? Prog. Neurobiol. 94 4 2012 389 407
150. D.D. Lofrumento, C. Saponaro, A. Cianciulli, F. De Nuccio, V. Mitolo, G. Nicolardi, and M.A. Panaro MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain Neuroimmunomodulation 18 2 2011 79 88
151. X.H. Lu, S.M. Fleming, B. Meurers, L.C. Ackerson, F. Mortazavi, V. Lo, D. Hernandez, D. Sulzer, G.R. Jackson, N.T. Maidment, M.F. Chesselet, and X.W. Yang Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein J. Neurosci. 29 7 2009 1962 1976
152. D.W. Luchtman, D. Shao, and C. Song Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease Physiol. Behav. 98 1-2 2009 130 138
153. D.W. Luchtman, Q. Meng, and C. Song Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease Behav. Brain Res. 226 2 2012 386 396
154. C.B. Lucking, A. Durr, V. Bonifati, J. Vaughan, G. De Michele, T. Gasser, B.S. Harhangi, G. Meco, P. Denefle, N.W. Wood, Y. Agid, and A. Brice Association between early-onset Parkinson's disease and mutations in the parkin gene N. Engl. J. Med. 342 21 2000 1560 1567
155. D. MacLeod, J. Dowman, R. Hammond, T. Leete, K. Inoue, and A. Abeliovich The familial Parkinsonism gene LRRK2 regulates neurite process morphology Neuron 52 4 2006 587 593
156. E.N. Mangano, D. Litteljohn, R. So, E. Nelson, S. Peters, C. Bethune, J. Bobyn, and S. Hayley Interferon-gamma plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways Neurobiol. Aging 33 7 2012 1411 1426
157. A.B. Manning-Bog, W.M. Caudle, X.A. Perez, S.H. Reaney, R. Paletzki, M.Z. Isla, V.P. Chou, A.L. McCormack, G.W. Miller, J.W. Langston, C.R. Gerfen, and D.A. Dimonte Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter Neurobiol. Dis. 27 2 2007 141 150
158. L.J. Martin, Y. Pan, A.C. Price, W. Sterling, N.G. Copeland, N.A. Jenkins, D.L. Price, and M.K. Lee Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death J. Neurosci. 26 1 2006 41 50
159. I. Martin, V.L. Dawson, and T.M. Dawson The impact of genetic research on our understanding of Parkinson's disease Prog. Brain Res. 183 2011 21 41
160. E.A. Mazzio, R.R. Reams, and K.F. Soliman The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro Brain Res. 2004 1-2 2004 29 44
161. M.K. McCoy, T.N. Martinez, K.A. Ruhn, D.E. Szymkowski, C.G. Smith, B.R. Botterman, K.E. Tansey, and M.G. Tansey Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease J. Neurosci. 26 37 2006 9365 9375
162. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 8 1988 1285 1291
163. S.O. McGuire, Z.D. Ling, J.W. Lipton, C.E. Sortwell, T.J. Collier, and P.M. Carvey Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons Exp. Neurol. 169 2 2001 219 230
164. P.B. Medawar Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye Br. J. Exp. Pathol. 29 1 1948 58 69
165. H.L. Melrose, J.C. Dachsel, B. Behrouz, S.J. Lincoln, M. Yue, K.M. Hinkle, C.B. Kent, E. Korvatska, J.P. Taylor, L. Witten, Y.Q. Liang, J.E. Beevers, M. Boules, B.N. Dugger, V.A. Serna, A. Gaukhman, X. Yu, M. Castanedes-Casey, A.T. Braithwaite, S. Ogholikhan, N. Yu, D. Bass, G. Tyndall, G.D. Schellenberg, D.W. Dickson, C. Janus, and M.J. Farrer Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice Neurobiol. Dis. 40 3 2010 503 517
166. G.E. Meredith, S. Totterdell, M. Beales, and C.K. Meshul Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease Exp. Neurol. 219 1 2009 334 340
167. M. Meulener, A.J. Whitworth, C.E. Armstrong-Gold, P. Rizzu, P. Heutink, P.D. Wes, L.J. Pallanck, and N.M. Bonini Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease Curr. Biol. 15 17 2005 1572 1577
168. J. Miklossy, D.D. Doudet, C. Schwab, S. Yu, E.G. McGeer, and P.L. McGeer Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys Exp. Neurol. 197 2 2006 275 283
169. M.S. Moehle, P.J. Webber, T. Tse, N. Sukar, D.G. Standaert, T.M. DeSilva, R.M. Cowell, and A.B. West LRRK2 inhibition attenuates microglial inflammatory responses J. Neurosci. 32 5 2012 1602 1611
170. M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients Neurosci. Lett. 180 2 1994 147 150
171. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1-2 1994 208 210
172. M. Mogi, M. Harada, T. Kondo, P. Riederer, and T. Nagatsu Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease J. Neural. Transm. Park Dis. Dement Sect. 9 1 1995 87 92
173. M. Mogi, M. Harada, T. Kondo, P. Riederer, and T. Nagatsu Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication J. Neural Transm. 103 8-9 1996 1077 1081
174. M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease Neurosci. Lett. 211 1 1996 13 16
175. M. Mogi, A. Togari, K. Tanaka, N. Ogawa, H. Ichinose, and T. Nagatsu Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506 Neurosci. Lett. 289 3 2000 165 168
176. M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu P53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain Neurosci. Lett. 414 1 2007 94 97
177. D.J. Moore, A.B. West, V.L. Dawson, and T.M. Dawson Molecular pathophysiology of Parkinson's disease Annu. Rev. Neurosci. 28 2005 57 87
178. H. Mortiboys, K.K. Johansen, J.O. Aasly, and O. Bandmann Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 Neurology 75 22 2010 2017 2020
179. M.P. Mount, A. Lira, D. Grimes, P.D. Smith, S. Faucher, R. Slack, H. Anisman, S. Hayley, and D.S. Park Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons J. Neurosci. 27 12 2007 3328 3337
180. R.B. Mythri, C. Venkateshappa, G. Harish, A. Mahadevan, U.B. Muthane, T.C. Yasha, M.M. Srinivas Bharath, and S.K. Shankar Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains Neurochem. Res. 36 8 2011 1452 1463
181. D. Narendra, A. Tanaka, D.F. Suen, and R.J. Youle Parkin is recruited selectively to impaired mitochondria and promotes their autophagy J. Cell. Biol. 183 5 2008 795 803
182. H.N. Nguyen, B. Byers, B. Cord, A. Shcheglovitov, J. Byrne, P. Gujar, K. Kee, B. Schule, R.E. Dolmetsch, W. Langston, T.D. Palmer, and R.R. Pera LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress Cell Stem Cell 8 3 2011 267 280
183. M. Nieto, F.J. Gil-Bea, E. Dalfo, M. Cuadrado, F. Cabodevilla, B. Sanchez, S. Catena, T. Sesma, E. Ribe, I. Ferrer, M.J. Ramirez, and T. Gomez-Isla Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice Neurobiol. Aging 27 6 2006 848 856
184. J. Niu, M. Yu, C. Wang, and Z. Xu Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin-like protein J. Neurochem. 122 3 2012 650 658
185. J.W. Langston, and P.C. Ballard Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease J. Neurol. Sci. 11 Suppl. 1 1984 160 165
186. J.A. Obeso, M.C. Rodriguez-Oroz, C.G. Goetz, C. Marin, J.H. Kordower, M. Rodriguez, E.C. Hirsch, M. Farrer, A.H. Schapira, and G. Halliday Missing pieces in the Parkinson's disease puzzle Nat. Med. 16 6 2010 653 661
187. E. Oestreicher, G.J. Sengstock, P. Riederer, C.W. Olanow, A.J. Dunn, and G.W. Arendash Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study Brain Res. 660 1 1994 8 18
188. C. Paisan-Ruiz, S. Jain, E.W. Evans, W.P. Gilks, J. Simon, M. van der Brug, A. Lopez de Munain, S. Aparicio, A.M. Gil, N. Khan, J. Johnson, J.R. Martinez, D. Nicholl, I.M. Carrera, A.S. Pena, R. de Silva, A. Lees, J.F. Marti-Masso, J. Perez-Tur, N.W. Wood, and A.B. Singleton Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 4 2004 595 600
189. J.J. Palacino, D. Sagi, M.S. Goldberg, S. Krauss, C. Motz, M. Wacker, J. Klose, and J. Shen Mitochondrial dysfunction and oxidative damage in parkin-deficient mice J. Biol. Chem. 279 18 2004 18614 18622
190. L. Parisiadou, C. Xie, H.J. Cho, X. Lin, X.L. Gu, C.X. Long, E. Lobbestael, V. Baekelandt, J.M. Taymans, L. Sun, and H. Cai Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis J. Neurosci. 29 44 2009 13971 13980
191. J. Park, S.B. Lee, S. Lee, Y. Kim, S. Song, S. Kim, E. Bae, J. Kim, M. Shong, J.M. Kim, and J. Chung Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin Nature 441 7097 2006 1157 1161
192. J.C. Paterna, A. Leng, E. Weber, J. Feldon, and H. Bueler DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice Mol. Ther. 15 4 2007 698 704
193. R. Pattarini, R.J. Smeyne, and J.I. Morgan Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrimidine model of Parkinson's disease Neuroscience 145 2 2007 654 668
194. F.A. Perez, W.R. Curtis, and R.D. Palmiter Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity BMC Neurosci. 6 2005 71
195. M. Periquet, O. Corti, S. Jacquier, and A. Brice Proteomic analysis of parkin knockout mice. alterations in energy metabolism, protein handling and synaptic function J. Neurochem. 95 5 2005 1259 1276
196. A.S. Perumal, V.B. Gopal, W.K. Tordzro, T.B. Cooper, and J.L. Cadet Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain Brain Res. Bull. 29 5 1992 699 701
197. V.H. Perry, C. Cunningham, and C. Holmes Systemic infections and inflammation affect chronic neurodegeneration Nat. Rev. Immunol. 7 2 2007 161 167
198. A. Petit, T. Kawarai, E. Paitel, N. Sanjo, M. Maj, M. Scheid, F. Chen, Y. Gu, H. Hasegawa, S. Salehi-Rad, L. Wang, E. Rogaeva, P. Fraser, B. Robinson, P. St George-Hyslop, and A. Tandon Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations J. Biol. Chem. 280 40 2005 34025 34032
199. E.D. Plowey, S.J. Cherra 3rd, Y.J. Liu, and C.T. Chu Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells J. Neurochem. 105 3 2008 1048 1056
200. H.F. Poon, M. Frasier, N. Shreve, V. Calabrese, B. Wolozin, and D.A. Butterfield Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice - a model of familial Parkinson's disease Neurobiol. Dis. 18 3 2005 492 498
201. M.C. Pott Godoy, R. Tarelli, C.C. Ferrari, M.I. Sarchi, and F.J. Pitossi Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease J. Neurol. 131 Pt 7 2008 1880 1894
202. M.G. Purisai, A.L. McCormack, S. Cumine, J. Li, M.Z. Isla, and D.A. Di Monte Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration Neurobiol. Dis. 25 2 2007 392 400
203. D. Ramonet, J.P. Daher, B.M. Lin, K. Stafa, J. Kim, R. Banerjee, M. Westerlund, O. Pletnikova, L. Glauser, L. Yang, Y. Liu, D.A. Swing, M.F. Beal, J.C. Troncoso, J.M. McCaffery, N.A. Jenkins, N.G. Copeland, D. Galter, B. Thomas, M.K. Lee, T.M. Dawson, V.L. Dawson, and D.J. Moore Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2 PLoS One 6 4 2011 e18568
204. S. Rathke-Hartlieb, P.J. Kahle, M. Neumann, L. Ozmen, S. Haid, M. Okochi, C. Haass, and J.B. Schulz Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice J. Neurochem. 77 4 2001 1181 1184
205. M. Rentzos, E. Evangelopoulos, E. Sereti, V. Zouvelou, S. Marmara, T. Alexakis, and I. Evdokimidis Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol. Scand. 125 4 2012 260 264
206. A.D. Reynolds, J.G. Glanzer, I. Kadiu, M. Ricardo-Dukelow, A. Chaudhuri, P. Ciborowski, R. Cerny, B. Gelman, M.P. Thomas, R.L. Mosley, and H.E. Gendelman Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease J. Neurochem. 104 6 2008 1504 1525
207. N.J. Riachi, J.C. LaManna, and S.I. Harik Entry of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine into the rat brain J. Pharmacol. Exp. Ther. 249 3 1989 744 748
208. J.A. Rodriguez-Navarro, M.J. Casarejos, J. Menendez, R.M. Solano, I. Rodal, A. Gomez, J.G. Yebenes, and M.A. Mena Mortality, oxidative stress and tau accumulation during ageing in parkin null mice J. Neurochem. 103 1 2007 98 114
209. M.C. Rodriguez-Oroz, M. Jahanshahi, P. Krack, I. Litvan, R. Macias, E. Bezard, and J.A. Obeso Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms Lancet Neurol. 8 12 2009 1128 1139
210. C. Roodveldt, J. Christodoulou, and C.M. Dobson Immunological features of alpha-synuclein in Parkinson's disease J. Cell. Mol. Med. 12 5B 2008 1820 1829
211. M.W. Rousseaux, P.C. Marcogliese, D. Qu, S.J. Hewitt, S. Seang, R.H. Kim, R.S. Slack, M.G. Schlossmacher, D.C. Lagace, T.W. Mak, and D.S. Park Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease Proc. Natl. Acad. Sci. USA 109 39 2012 15918 15923
212. S. Saha, M.D. Guillily, A. Ferree, J. Lanceta, D. Chan, J. Ghosh, C.H. Hsu, L. Segal, K. Raghavan, K. Matsumoto, N. Hisamoto, T. Kuwahara, T. Iwatsubo, L. Moore, L. Goldstein, M. Cookson, and B. Wolozin LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans J. Neurosci. 29 29 2009 9210 9218
213. R. Sanchez-Pernaute, A. Ferree, O. Cooper, M. Yu, A.L. Brownell, and O. Isacson Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease J. Neuroinflammation 1 1 2004 6
214. T.K. Sang, H.Y. Chang, G.M. Lawless, A. Ratnaparkhi, L. Mee, L.C. Ackerson, N.T. Maidment, D.E. Krantz, and G.R. Jackson A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine J. Neurosci. 27 5 2007 981 992
215. N. Schintu, L. Frau, M. Ibba, A. Garau, E. Carboni, and A.R. Carta Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease Neurotox. Res. 16 2 2009 127 139
216. T.B. Sherer, R. Betarbet, J.H. Kim, and J.T. Greenamyre Selective microglial activation in the rat rotenone model of Parkinson's disease Neurosci. Lett. 341 2 2003 87 90
217. T.B. Sherer, R. Betarbet, C.M. Testa, B.B. Seo, J.R. Richardson, J.H. Kim, G.W. Miller, T. Yagi, A. Matsuno-Yagi, and J.T. Greenamyre Mechanism of toxicity in rotenone models of Parkinson's disease J. Neurosci. 23 34 2003 10756 10764
218. T.B. Sherer, J.H. Kim, R. Betarbet, and J.T. Greenamyre Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation Exp. Neurol. 179 1 2003 9 16
219. K. Shimizu, K. Ohtaki, K. Matsubara, K. Aoyama, T. Uezono, O. Saito, M. Suno, K. Ogawa, N. Hayase, K. Kimura, and H. Shiono Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat Brain Res. 906 1-2 2001 135 142
220. H. Shimura, N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, S. Minoshima, N. Shimizu, K. Iwai, T. Chiba, K. Tanaka, and T. Suzuki Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat. Genet. 25 3 2000 302 305
221. H. Shimura, Y. Mizuno, and N. Hattori Parkin and parkinson disease Clin. Chem. 58 8 2012 1260 1261
222. R. Smeyne, and V. Jackson-Lewis The MPTP model of Parkinson's disease Brain Res. Mol. Brain Res. 134 1 2005 57
223. W.W. Smith, Z. Pei, H. Jiang, V.L. Dawson, T.M. Dawson, and C.A. Ross Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9 10 2006 1231 1233
224. R.M. Solano, M.J. Casarejos, J. Menendez-Cuervo, J.A. Rodriguez-Navarro, J. Garcia de Yebenes, and M.A. Mena Glial dysfunction in parkin null mice. Effects of aging J. Neurosci. 28 3 2008 598 611
225. D.D. Song, C.W. Shults, A. Sisk, E. Rockenstein, and E. Masliah Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP Exp. Neurol. 186 2 2004 158 172
226. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 6645 1997 839 840
227. Sreejayan, and M.N. Rao Nitric oxide scavenging by curcuminoids J. Pharm. Pharmacol. 49 1 1997 105 107
228. K. Sriram, J.M. Matheson, S.A. Benkovic, D.B. Miller, M.I. Luster, and J.P. O'Callaghan Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease FASEB J. 16 11 2002 1474 1476
229. M.G. Tansey, and M.S. Goldberg Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention Neurobiol. Dis. 37 3 2010 510 518
230. M.G. Tansey, M.K. McCoy, and T.C. Frank-Cannon Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention Exp. Neurol. 208 1 2007 1 25
231. M. Thiruchelvam, B.J. Brockel, E.K. Richfield, R.B. Baggs, and D.A. Cory-Slechta Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res. 873 2 2000 225 234
232. K.J. Thomas, M.K. McCoy, J. Blackinton, A. Beilina, M. van der Brug, A. Sandebring, D. Miller, D. Maric, A. Cedazo-Minguez, and M.R. Cookson DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy Hum. Mol. Genet. 20 1 2011 40 50
233. Y. Tong, H. Yamaguchi, E. Giaime, S. Boyle, R. Kopan, R.J. Kelleher 3rd, and J. Shen Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice Proc. Natl. Acad. Sci. USA 107 21 2010 9879 9884
234. T.A. Tran, A.D. Nguyen, J. Chang, M.S. Goldberg, J.K. Lee, and M.G. Tansey Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B PLoS One 6 8 2011 e23660
235. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, S. Gispert, Z. Ali, D. Del Turco, A.R. Bentivoglio, D.G. Healy, A. Albanese, R. Nussbaum, R. Gonzalez-Maldonado, T. Deller, S. Salvi, P. Cortelli, W.P. Gilks, D.S. Latchman, R.J. Harvey, B. Dallapiccola, G. Auburger, and N.W. Wood Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 5674 2004 1158 1160
236. M. Varcin, E. Bentea, Y. Michotte, and S. Sarre Oxidative stress in genetic mouse models of Parkinson's disease Oxid. Med. Cell. Longev. 2012 2012 624925
237. K. Venderova, G. Kabbach, E. Abdel-Messih, Y. Zhang, R.J. Parks, Y. Imai, S. Gehrke, J. Ngsee, M.J. Lavoie, R.S. Slack, Y. Rao, Z. Zhang, B. Lu, M.E. Haque, and D.S. Park Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease Hum. Mol. Genet. 18 22 2009 4390 4404
238. J. Waak, S.S. Weber, A. Waldenmaier, K. Gorner, M. Alunni-Fabbroni, H. Schell, D. Vogt-Weisenhorn, T.T. Pham, V. Reumers, V. Baekelandt, W. Wurst, and P.J. Kahle Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1 FASEB J. 23 8 2009 2478 2489
239. D. Wang, B. Tang, G. Zhao, Q. Pan, K. Xia, R. Bodmer, and Z. Zhang Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons Mol. Neurodegener. 3 2008 3
240. M.B. Watson, F. Richter, S.K. Lee, L. Gabby, J. Wu, E. Masliah, R.B. Effros, and M.F. Chesselet Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein Exp. Neurol. 237 2 2012 318 334
241. A.B. West, D.J. Moore, C. Choi, S.A. Andrabi, X. Li, D. Dikeman, S. Biskup, Z. Zhang, K.L. Lim, V.L. Dawson, and T.M. Dawson Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity Hum. Mol. Genet. 16 2 2007 223 232
242. A.J. Whitworth, D.A. Theodore, J.C. Greene, H. Benes, P.D. Wes, and L.J. Pallanck Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease Proc. Natl. Acad. Sci. USA 102 22 2005 8024 8029
243. A. Williams, and D. Ramsden Autotoxicity, methylation and a road to the prevention of Parkinson's disease J. Clin.Neurosci. 12 1 2005 6
244. H. Yamaguchi, and J. Shen Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice Mol. Neurodegener. 2 2007 10
245. L. Yang, S. Sugama, J.W. Chirichigno, J. Gregorio, S. Lorenzl, D.H. Shin, S.E. Browne, Y. Shimizu, T.H. Joh, M.F. Beal, and D.S. Albers Minocycline enhances MPTP toxicity to dopaminergic neurons J. Neurosci. Res. 74 2 2003 278 285
246. D. Yang, T. Li, Z. Liu, N. Arbez, J. Yan, T.H. Moran, C.A. Ross, and W.W. Smith LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin Neurobiol. Dis. 47 3 2012 385 392
247. C. Yao, R. El Khoury, W. Wang, T.A. Byrd, E.A. Pehek, C. Thacker, X. Zhu, M.A. Smith, A.L. Wilson-Delfosse, and S.G. Chen LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease Neurobiol. Dis. 40 1 2010 73 81
248. Y. Yasuda, R. Shinagawa, M. Yamada, T. Mori, N. Tateishi, and S. Fujita Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Brain Res. 1138 2007 196 202
249. Z. Yue, and M.L. Lachenmayer Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications Mov. Disord. 26 8 2011 1386 1397
250. W. Zhang, T. Wang, Z. Pei, D.S. Miller, X. Wu, M.L. Block, B. Wilson, Y. Zhou, J.S. Hong, and J. Zhang Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB J. 19 6 2005 533 542
251. W. Zhang, K. Phillips, A.R. Wielgus, J. Liu, A. Albertini, F.A. Zucca, R. Faust, S.Y. Qian, D.S. Miller, C.F. Chignell, B. Wilson, V. Jackson-Lewis, S. Przedborski, D. Joset, J. Loike, J.S. Hong, D. Sulzer, and L. Zecca Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease Neurotox. Res. 19 1 2011 63 72
252. F. Zhou, J.Y. Wu, X.L. Sun, H.H. Yao, J.H. Ding, and G. Hu Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation Neuropsychopharmacology 32 12 2007 2570 2580
253. H. Zhou, C. Huang, J. Tong, and X.G. Xia Early exposure to paraquat sensitizes dopaminergic neurons to subsequent silencing of PINK1 gene expression in mice J. Biol. Sci. 7 8 2011 1180 1187
254. X.R. Zhu, L. Maskri, C. Herold, V. Bader, C.C. Stichel, O. Gunturkun, and H. Lubbert Non-motor behavioural impairments in parkin-deficient mice Eur. J. Neurosci. 26 7 2007 1902 1911
255. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R.J. Uitti, D.B. Calne, A.J. Stoessl, R.F. Pfeiffer, N. Patenge, I.C. Carbajal, P. Vieregge, F. Asmus, B. Muller-Myhsok, D.W. Dickson, T. Meitinger, T.M. Strom, Z.K. Wszolek, and T. Gasser Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 4 2004 601 607